Ganschow Rainer, Maucksch Christof
From the Department of Pediatrics, University Children's Hospital, Bonn, Germany.
Albireo Pharma, Inc., Boston, MA.
JPGN Rep. 2023 Mar 24;4(2):e301. doi: 10.1097/PG9.0000000000000301. eCollection 2023 May.
A male pediatric patient with elevated liver enzyme and bile acid levels, bile duct hypoplasia, mild liver fibrosis, and pruritus was initially diagnosed with progressive familial intrahepatic cholestasis. The patient did not respond to treatments of ursodeoxycholic acid and naltrexone. Subsequent treatment with odevixibat resulted in improvements in serum bile acid levels and pruritus within a few weeks of initiation. During the course of odevixibat treatment, genetic testing results and additional clinical findings indicated a diagnosis of Alagille syndrome, a condition that shares some clinical features with progressive familial intrahepatic cholestasis. Odevixibat treatment was continued off label, during which time the patient's serum bile acid levels dropped to within the normal limit and pruritus was completely ameliorated. This report suggests odevixibat may be an effective treatment option for Alagille syndrome.
一名肝酶和胆汁酸水平升高、胆管发育不全、轻度肝纤维化且伴有瘙痒的男性儿科患者最初被诊断为进行性家族性肝内胆汁淤积症。该患者对熊去氧胆酸和纳曲酮治疗无反应。随后使用odevixibat进行治疗,在开始治疗后的几周内血清胆汁酸水平和瘙痒症状有所改善。在odevixibat治疗过程中,基因检测结果和其他临床发现表明该患者被诊断为阿拉吉耶综合征,这是一种与进行性家族性肝内胆汁淤积症有一些共同临床特征的疾病。odevixibat治疗在标签外持续进行,在此期间患者的血清胆汁酸水平降至正常范围,瘙痒症状完全缓解。本报告表明odevixibat可能是治疗阿拉吉耶综合征的一种有效选择。